Nuveen Asset Management LLC Reduces Stake in Harrow, Inc. (NASDAQ:HROW)

Nuveen Asset Management LLC cut its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 65.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 113,752 shares of the company's stock after selling 215,172 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.32% of Harrow worth $3,816,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of HROW. Tower Research Capital LLC TRC raised its holdings in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Harrow during the fourth quarter valued at about $78,000. AlphaQuest LLC grew its position in shares of Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares in the last quarter. Federated Hermes Inc. purchased a new position in shares of Harrow during the fourth quarter valued at about $214,000. Finally, Maridea Wealth Management LLC purchased a new position in shares of Harrow during the fourth quarter valued at about $222,000. 72.76% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HROW. HC Wainwright raised their price objective on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, May 12th. B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.

Harrow Trading Down 2.7%

HROW traded down $0.79 on Thursday, hitting $28.72. The company had a trading volume of 469,481 shares, compared to its average volume of 498,650. The company has a market cap of $1.05 billion, a PE ratio of -30.55 and a beta of 0.41. Harrow, Inc. has a 12-month low of $16.87 and a 12-month high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The business's fifty day simple moving average is $25.36 and its 200 day simple moving average is $30.16.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Equities research analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.